Cue Biopharma, Inc. (CUE)

NASDAQ: CUE · Real-Time Price · USD
0.8580
+0.1056 (14.04%)
At close: Oct 8, 2025, 4:00 PM EDT
0.8580
0.00 (0.00%)
Pre-market: Oct 9, 2025, 4:15 AM EDT
14.04%
Market Cap65.93M
Revenue (ttm)8.29M
Net Income (ttm)-38.90M
Shares Out 76.85M
EPS (ttm)-0.53
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume600,974
Open0.7800
Previous Close0.7524
Day's Range0.7674 - 0.8600
52-Week Range0.5406 - 1.9890
Beta1.55
AnalystsStrong Buy
Price Target3.00 (+249.65%)
Earnings DateNov 13, 2025

About CUE

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in p... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 2, 2018
Employees 41
Stock Exchange NASDAQ
Ticker Symbol CUE
Full Company Profile

Financial Performance

In 2024, Cue Biopharma's revenue was $9.29 million, an increase of 69.16% compared to the previous year's $5.49 million. Losses were -$40.67 million, -19.83% less than in 2023.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for CUE stock is "Strong Buy." The 12-month stock price target is $3.0, which is an increase of 249.65% from the latest price.

Price Target
$3.0
(249.65% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates

Usman Azam, M.D., is appointed President and Chief Executive Officer of Cue Biopharma, effective September 29, 2025 Daniel Passeri, Chief Executive Officer of Cue Biopharma, transitions to Strategic A...

9 days ago - GlobeNewsWire

Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference

BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modu...

7 weeks ago - GlobeNewsWire

Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme

BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modu...

2 months ago - GlobeNewsWire

Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod...

2 months ago - GlobeNewsWire

Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer

Additional complete response (CR) observed in patient with multiple tumors Confirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients...

3 months ago - GlobeNewsWire

Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies

ORR of 50% in treatment-naïve patients with HPV+ R/M HNSCC 12-month landmark survival of 88% and mOS of 32 months

3 months ago - GlobeNewsWire

Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease

CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 CUE-401, a first-in-class bispeci...

3 months ago - GlobeNewsWire

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments

5 months ago - GlobeNewsWire

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08, 2025 (GLOBE ...

5 months ago - GlobeNewsWire

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modul...

5 months ago - GlobeNewsWire

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Cue Biopharma, Inc. (NASDAQ:CUE) Business Update Call April 15, 2025 4:30 PM ET Company Participants Eric Ribner - LifeSci Advisors Dan Passeri - Chief Executive Officer Lucinda Warren - Chief Busine...

6 months ago - Seeking Alpha

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Ingelheim, Germany, and Boston, MA, USA, April 14, 2025 – Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop...

6 months ago - GlobeNewsWire

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod...

6 months ago - GlobeNewsWire

Cue Biopharma Announces Proposed Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod...

6 months ago - GlobeNewsWire

Cue Biopharma to Host Business Update Call and Webcast

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod...

6 months ago - GlobeNewsWire

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and m...

6 months ago - GlobeNewsWire

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage a...

11 months ago - GlobeNewsWire

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modu...

11 months ago - GlobeNewsWire

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod...

11 months ago - GlobeNewsWire

Cue Biopharma Announces Strategic Organizational Transition

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modu...

11 months ago - GlobeNewsWire

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modu...

11 months ago - GlobeNewsWire

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modu...

1 year ago - GlobeNewsWire

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod...

1 year ago - GlobeNewsWire

Cue Biopharma Announces Proposed Public Offering

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod...

1 year ago - GlobeNewsWire

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and mod...

1 year ago - GlobeNewsWire